Zurück zu Projekte

17003.1 PFLS-LS

Development of stable affinity columns for antibody purification

Zusammenfassung

Development of stable affinity columns for antibody purification

Weitere Texte

Abstract

Monoclonal antibodies (MAbs) account for a large share of the rapidly growing biological drugs|market. Whilst the market for such drugs is expected to reach $62.3 billion in 2015, the biggest|obstacle in MAb production ¿ purification, is still suboptimal. Expensive Protein A resins are|used but they can be sensitive to elution and sterilization conditions. In combination with|ChromaCon¿s proprietary technology, this project aims to develop and commercialize a novel,|efficient and cost effective antibody purification process using a novel affinity reagent for|humanized antibodies.

Beteiligte

Michael Bavand

Wirtschaftspartner

michael.bavand@chromacon.ch

ChromaCon AG Michael Bavand Technoparkstrasse 1 8005 Zürich ZH CH

Jeffrey Bode

Kontaktperson

bode@org.chem.ethz.ch

ETH Zürich Jeffrey Bode Wolfgang-Pauli-Strasse 10 8093 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2015-01-31
Enddatum
2017-10-31
Bewilligte Gesamtkosten
CHF 368184.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%